BioPharm International-06-01-2003

BioPharm International

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

June 15, 2003

Columns and Departments

16

6

by BioPharm International staff

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

June 15, 2003

In Search of the Optimum biotech Strategy

16

6

by Peter Loupos, Aventis Drug Innovation and Approval and Andrew Grygiel A collaborative framework can be a driver for cultural change, encouraging knowledge sharing between internal and external personnel and improving innovation and productivity throughout the enterprise.

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection

June 15, 2003

Detecting and Accounting for Variability

16

6

by Chandrashekar Ganesa, Genzyme Corporation, Brian W. Granda, and Robert J. Mattaliano

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

June 15, 2003

In Search of the Optimum biotech Strategy

16

6

by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.

The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry

June 15, 2003

In Search of the Optimum biotech Strategy

16

6

by Ellis Wilson, AstraZeneca Pharmaceuticals, James McDonough, William Allbee, and Jann Nielsen Compared with their big pharma counterparts, biotech project managers earn more advanced degrees, have fewer years' experience in the industry, and more frequently classify their role as "senior management."

Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development

June 15, 2003

In Search of the Optimum biotech Strategy

16

6

by Bruce Babbitt, PAREXEL International, JanHasker Jonkman, and Paul McKim By partnering with external drug development service providers, small biopharmaceutical start-ups can move their products out of the lab and into clinical development more efficiently.

Inside Washington: Reshaping Biotech Drug Development

June 15, 2003

Columns and Departments

16

6

by Jill Wechsler, BioPharm International FDA is examining policy options for incorporating genomic information into the regulatory process while encouraging manufacturers to share pharmacogenomic research.

BioTrends: M&A Malaise

June 15, 2003

Columns and Departments

16

6

by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.